Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
Valeant Pharmaceuticals International, Inc.
Index- P/E49.20 EPS (ttm)1.77 Insider Own2.30% Shs Outstand339.62M Perf Week3.68%
Market Cap29.58B Forward P/E5.95 EPS next Y14.63 Insider Trans-41.37% Shs Float335.76M Perf Month-25.56%
Income605.10M PEG2.15 EPS next Q3.56 Inst Own66.80% Short Float3.83% Perf Quarter-63.12%
Sales9.99B P/S2.96 EPS this Y198.90% Inst Trans20.80% Short Ratio0.95 Perf Half Y-63.62%
Book/sh18.39 P/B4.74 EPS next Y30.36% ROA1.50% Target Price- Perf Year-39.83%
Cash/sh4.18 P/C20.83 EPS next 5Y22.88% ROE9.90% 52W Range69.33 - 263.81 Perf YTD-39.14%
Dividend- P/FCF14.23 EPS past 5Y19.20% ROI8.40% 52W High-66.99% Beta0.74
Dividend %- Quick Ratio1.20 Sales past 5Y58.70% Gross Margin75.00% 52W Low25.62% ATR10.09
Employees16800 Current Ratio1.50 Sales Q/Q35.50% Oper. Margin19.20% RSI (14)40.61 Volatility7.66% 10.24%
OptionableYes Debt/Eq4.87 EPS Q/Q-82.70% Profit Margin6.10% Rel Volume0.32 Prev Close87.02
ShortableYes LT Debt/Eq4.76 EarningsOct 19 BMO Payout0.00% Avg Volume13.45M Price87.09
Recom3.00 SMA202.07% SMA50-36.23% SMA200-56.55% Volume4,218,700 Change0.08%
Nov-20-15Reiterated Mizuho Buy $155 → $111
Nov-17-15Reiterated Morgan Stanley Equal-Weight $200 → $98
Nov-11-15Reiterated Stifel Buy $285 → $200
Nov-11-15Reiterated RBC Capital Mkts Outperform $213 → $206
Nov-11-15Reiterated JP Morgan Overweight $265 → $225
Nov-06-15Reiterated Guggenheim Buy $300 → $195
Nov-03-15Reiterated RBC Capital Mkts Outperform $231 → $213
Nov-02-15Reiterated Jefferies Buy $224 → $172
Nov-02-15Downgrade Goldman Buy → Neutral
Oct-30-15Reiterated UBS Buy $285 → $255
Oct-27-15Upgrade Mizuho Neutral → Buy $155
Oct-27-15Reiterated RBC Capital Mkts Outperform $250 → $231
Oct-27-15Reiterated Barclays Overweight $300 → $135
Oct-20-15Downgrade CIBC Sector Outperform → Sector Perform
Oct-09-15Initiated Mizuho Neutral
Oct-02-15Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-30-15Initiated BofA/Merrill Buy
Sep-29-15Initiated Nomura Buy $290
Jul-27-15Reiterated Morgan Stanley Overweight $235 → $284
May-26-15Reiterated RBC Capital Mkts Outperform $249 → $265
Nov-27-15 07:14AM  The SEC Is Fast Asleep While KaloBios Is Rampantly Manipulated at Forbes
Nov-26-15 11:42PM  Cost of Skin Drugs Rising Rapidly, Study Shows at The Wall Street Journal
01:57PM  Cost of Skin Drugs Rising Rapidly, Study Shows at The Wall Street Journal
10:56AM  Study: Skin care drug prices up 401 percent since 2009
10:37AM  Canada Stocks Rise on Metals Rally as China Considers Measures at Bloomberg
Nov-25-15 05:21PM  U.S. court rejects Linden Care's request for temporary restraining order Reuters
05:01PM  Valeant, Glaxo, Novartis Skin Drug Prices Have Soared at Investor's Business Daily
04:33PM  Valeant shares seesaw after hedge fund links drugmaker to more pharmacies at USA TODAY
03:48PM  Synthetic Stock: How Ackman Doubled-Down on VRX
01:27PM  Do Hedge Funds Love Barclays PLC (ADR) (BCS)? at Insider Monkey
12:08PM  Valeant, Philidor and the Name Game at The Wall Street Journal
11:38AM  Why Junk Bonds Don't Necessarily Spell Doom for Stocks at
11:07AM  Canada Stocks Erase Gains as Grocers Rise, Valeant Rally Fizzles at Bloomberg
10:18AM  Market Humbles High Intensity Players at Forbes
09:46AM  Hedge Fund Questions Alleged Valeant Ties to More Pharmacies at Bloomberg
09:43AM  Big Pharma has become addicted to an illusion at Financial Times
08:35AM  A.M. Funds Roundup: No Escaping Bond ETF Liquidity; Balancing Market Timing And Groupthink at
Nov-24-15 04:52PM  ValueAct, Too, Was Hit Hard By Valeant at
04:48PM  Bill Ackman Found a Cheap Way to Buy More Valeant Stock
04:31PM  Cloning Alpha Alphaclone and others
04:15PM  Stocks Are Hardly Getting Into the Holiday Spirit at TheStreet
12:53PM  Tuesday links: good storytellers
11:59AM  Valeant Pharmaceuticals: Ackman Ups Stake, While ValueAct Digs In
11:19AM  Stocks Fall, Crude Rallies on Russia-Turkey Tensions at TheStreet
11:10AM  Does Recent Biotech Volatility Signal Tougher Times Ahead? at Forbes
10:22AM  Stocks Tumble as Russia-Turkey Relations Break Down at TheStreet
09:48AM  Billionaire Bill Ackman Puts His Money Where His Mouth Is, While Carl Icahn Reveals His Newest Activist Target at Insider Monkey
09:30AM  Zacks Industry Outlook Highlights: Valeant, Pfizer, Allergan, AbbVie and Gilead
09:22AM  Valeant (VRX) Stock Climbs as Ackman Ups Stake to 9.9% at TheStreet
07:16AM  10 things you need to know before the opening bell
06:58AM  Nov. 24 Premarket Briefing: 10 Things You Should Know at TheStreet
06:24AM  Big moves in activism
12:30AM  [$$] Ackmans Pershing Square Boosts Stake in Valeant to 9.9% at The Wall Street Journal
Nov-23-15 08:19PM  Pershing Square invests more in Valeant after controversy at MarketWatch
07:42PM  [$$] Ackman's Pershing Square Boosts Stake in Valeant to 9.9% at The Wall Street Journal
07:14PM  Bill Ackman Boosts Valeant Pharmaceuticals Stake To 9.9% Amid Scandal at Forbes
06:56PM  Ackman's Pershing boosts stake in Valeant Pharmaceuticals
06:45PM  Ackman boosts stake in drugmaker Valeant
06:40PM  Exclusive: ValueAct gains for the year wiped out by Valeant loss
05:45PM  Bill Ackman's Pershing raises stake in Valeant to 9.9% at MarketWatch
05:31PM  Ackman's Pershing Square Increases Valeant Stake to 9.9% at Bloomberg
05:31PM  Ackman's Pershing Square Increases Valeant Stake to 9.9%
05:27PM  Bill Ackman just boosted his stake in Valeant to 9.9% from 5.7%
05:22PM  Ackman raises Valeant stake to 9.9%
03:40PM  Hedge-fund diversification shrinks after rout in health-care sector at MarketWatch
02:01PM  Hedge Funds' Favorite Stocks Are Getting Whooped By The S&P 500 at
01:01PM  Where hedge funds are putting their money
10:32AM  Hedge funds' top stock picks haven't been smoked this badly since the financial crisis
10:28AM  10 Stocks to Pick Up in December
09:44AM  The Pfizer-Allergan Merger Maybe Dwarfed By The Merck-ExpressScripts Divide at Forbes
07:50AM  Mallinckrodt, Horizon shares fall as concerns about Valeant business model spread at
12:21AM  Concerns Over Valeant Spread to Other Drug Makers at The Wall Street Journal
Nov-22-15 08:45PM  Concerns Over Valeant Spread to Other Drug Makers at The Wall Street Journal
Nov-21-15 01:00PM  3 Stocks Wall Street Hates at Motley Fool
11:38AM  Investing rule No. 1: Do your own work
09:03AM  Jeffrey Ubbens Top 5 Q4 Stock Picks at Insider Monkey
08:15AM  KaloBios, Valeant Lead Week's 5 Top Drug Stock Gainers at Investor's Business Daily
12:01AM  [$$] The Whole Story at Express Scripts at
Nov-20-15 10:00PM  VALEANT ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Fund Managers, Institutional and Large Individual Investors with Losses in Excess of $1 million of Lead Plaintiff Deadline in Class Action Lawsuit Against Va PR Newswire +8.33%
05:46PM  Novartis Admits To Valeant-like Pharmacy Scheme in $390 Million Settlement at Fortune
05:43PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Valeant Pharmaceuticals International, Inc. - VRX GlobeNewswire
04:30PM  Imperva Will Continue Yearlong Uptrend (Plus: PFPT, XCO, VRX, NKE)
04:20PM  Hedge Funds Are Dumping Valeant Pharmaceuticals Intl Inc (VRX); Should You? at Insider Monkey
04:00PM  Jeffrey Sonnenfeld: What the heck, biotech?
03:45PM  Proofpoint Will Continue to Rise (Plus: XCO, VRX, NKE)
03:44PM  Which Stock Picks Havent Worked for the ClearBridge Aggressive Growth Fund?
02:47PM  Can You Pick the Guys Who Pick the Guys Who Pick the Best Stocks? at The Wall Street Journal
02:25PM  Buy Into EXCO as a Low-Priced Play (Plus: VRX, NKE)
01:46PM  Valeant Pharmaceuticals (VRX) Stock Could Make a Valiant Comeback at TheStreet
01:15PM  Valeant Pharmaceuticals Could Make A Valiant Comeback (Plus: NKE)
12:50PM  Valeant to Up Incentives to Retain Key Employees Amid Turmoil
12:44PM  Bill Ackman's Pershing Square Hedge Fund Is Hanging On to This Scandal-Ridden Company at Motley Fool
10:36AM  This May be Biotechs Next Huge Winner
10:32AM  Why Allergan Could Be the Buyer of Pfizer at The Wall Street Journal
10:30AM  VRX Investor Deadline Alert: Law Offices of Howard G. Smith Reminds Valeant Pharmaceuticals, Inc. Investors of Upcoming Lead Plaintiff Deadline Business Wire
08:43AM  Valeant to host investor day on Dec. 16, discuss forecast, business
08:41AM  How 1 Specialty-Drug Maker Hopes to Win Back Investor Trust at Motley Fool
08:39AM  Should You Own Lone Pine Capital's 3 Favorite Stocks? at Motley Fool
08:15AM  Concentrated Mutual Funds: Leaving Too Much to Luck
08:00AM  /C O R R E C T I O N -- Valeant Pharmaceuticals International, Inc./ PR Newswire
08:00AM  /C O R R E C T I O N -- Valeant Pharmaceuticals International, Inc./ CNW Group
07:07AM  Why you should never short-sell stocks at MarketWatch
Nov-19-15 07:12PM  Valeant Pharma Autopsy: Counting the Lost Billions +15.70%
04:46PM  Valeant enjoys big rebound after Citigroup gives thumbs up at MarketWatch
04:35PM  The Valeant News No One Is Talking About
04:06PM  CANADA STOCKS-TSX rises on mining, financial gains; Valeant surges
03:52PM  Valeant Shares Surge as Credit Analyst Says Reaction Overdone at Bloomberg
03:32PM  Why Valeant Pharmaceuticals Intl Inc Was Incentivized to Climb Higher Today at Motley Fool
02:10PM  Here's Why Valeant (VRX) Stock Is Soaring Today at TheStreet
01:26PM  Bill Ackmans hedge fund sinks 24.5% as Valeant craters at MarketWatch
01:23PM  JPM and BAC Rose Due to the Likelihood of a Rate Hike
12:40PM  Four Stocks That Have Investors Buzzing Today at Insider Monkey
10:48AM  Canadian Stocks Rise a 2nd Day as Valeant, Raw-Materials Rally at Bloomberg
09:46AM  Billionaire Stephen Mandel Remains Among Valeant Bulls; Betting Big on Tech in Q4 at Insider Monkey
09:25AM  Billionaire Leon Coopermans Big Moves On Valeant, Facebook, GM, More at Insider Monkey
Nov-18-15 06:35PM  Ackman's Pershing Square Holdings off 24.5 percent YTD
06:31PM  Ackman's Pershing Square Holdings off 24.5 pct YTD
06:24PM  INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 From Investment in Valeant Pharmaceuticals International, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit -- GlobeNewswire
03:09PM  Valeant (VRX) Stock Climbs, Incentivizing Staff Against Leaving at TheStreet
02:10PM  Moody's: Side Effects of Pharma Price Scrutiny Will Stem CLO Gains from M&A Activity at Moody's
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer. It also provides Zovirax, an antiviral for recurrent herpes labialis and initial genital herpes; Syprine to treat patients with Wilson's disease; Elidel to treat atopic dermatitis; Prolensa for inflammation and pain following cataract surgery; Duromine, a weight loss drug; and Lotemax gel for post-operative inflammation and pain. In addition, the company offers PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; ReNu Multiplus to lubricate and rewet soft contact lenses; Biotrue for healthy contact lens wear; Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; AntiGrippin for acute respiratory and respiratory viral diseases, and influenza; and Bedoyecta, a vitamin B complex product. Further, it provides SofLens daily disposable contact lenses; PureVision, a contact lens; various ophthalmic surgical products; Biotrue ONEday lens; medical device systems for aesthetic applications; and Bausch + Lomb Ultra, a contact lens. Additionally, the company offers Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Cardizem CD to treat hypertension and angina; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pearson J. MichaelChief Executive OfficerNov 05Sale78.481,297,399101,825,9701,514,664Nov 09 05:24 PM
Farmer Ronald HaroldDirectorOct 21Buy181.601,500272,39515,532Oct 22 05:09 PM
Farmer Ronald HaroldDirectorAug 26Buy220.00500110,0002,000Aug 27 04:33 PM
Farmer Ronald HaroldDirectorAug 21Buy224.971,000224,9731,500Aug 25 04:47 PM
Rosiello Robert L.EVP, Chief Financial OfficerJul 31Buy257.25704181,104441,675Aug 03 04:54 PM
Rosiello Robert L.EVP, Chief Financial OfficerJul 30Buy253.997,1711,821,362440,971Aug 03 04:54 PM
Rosiello Robert L.Executive Vice PresidentJun 12Buy232.5112,9002,999,37912,900Jun 16 04:01 PM
UBBEN JEFFREY WDirectorJun 10Sale220.244,200,000925,011,6131,059,793Jun 12 07:23 PM
Farmer Ronald HaroldDirectorJun 09Buy232.05500116,025500Jun 10 05:02 PM
Farmer Ronald HaroldDirectorJun 08Buy289.20500144,60035,426Jun 10 05:02 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 02Option Exercise51.0114,900760,04951,575Jun 03 05:45 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 02Sale238.0037,9009,020,31813,675Jun 03 05:45 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 01Option Exercise51.011005,10136,775Jun 03 05:45 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 01Sale240.0010024,00036,675Jun 03 05:45 PM
Whitaker Anne ClemDirectorMay 26Buy234.677,5001,760,0007,500May 27 04:29 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMay 05Option Exercise6.1021,807133,02364,994May 06 05:51 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMay 04Option Exercise25.4290,9382,311,644134,125May 06 05:51 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMay 04Sale222.5490,93820,237,44343,187May 06 05:51 PM
Kornwasser LaizerEVP, Company Group ChairmanApr 17Option Exercise0.0045,0000123,377Apr 21 05:46 PM
Mirovsky PavelPresident, EMENAApr 15Option Exercise0.0024,175034,175Apr 17 05:28 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMar 03Option Exercise6.1021,808133,02943,187Mar 04 05:24 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMar 02Option Exercise25.4290,9392,311,669112,296Mar 04 05:24 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMar 02Sale200.0190,93918,189,09121,379Mar 04 05:24 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMEAFeb 27Option Exercise0.0010,000010,000Mar 02 05:16 PM
Stolz Brian M.EVP, Administration and CHCOJan 22Option Exercise0.007,350095,934Jan 26 05:22 PM
Schiller Howard BradleyEVP, Chief Financial OfficerJan 05Option Exercise0.0045,0000318,714Jan 07 05:38 PM
Stolz Brian M.EVP, CHCO and AdministrationDec 23Option Exercise0.0015,426096,618Dec 24 10:31 AM
Farmer Ronald HaroldDirectorDec 12Buy160.4850080,24033,004Dec 16 02:59 PM
UBBEN JEFFREY WDirectorDec 10Buy139.2950,0006,964,50018,030,936Dec 11 06:59 PM
UBBEN JEFFREY WDirectorDec 09Buy140.25200,00028,050,00017,980,936Dec 11 06:59 PM
STEVENSON KATHARINE BERGHUISDirectorDec 03Buy145.731,500218,59523,098Dec 03 04:48 PM